Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Clinical trial NCT04309240 · UNKNOWN

Trial details

NCT number: NCT04309240
Sponsor: LiuZhou People's Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Rivaroxaban Thromboprophylaxis Cancer

Start date: 2020-03-08
Primary completion: 2022-03-08
Enrollment: 204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.